Published in Vet Comp Oncol on June 13, 2013
Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol (1984) 2.41
Aurora kinase inhibitors--rising stars in cancer therapeutics? Mol Cancer Ther (2010) 1.91
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One (2009) 1.55
Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res (2008) 1.50
Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc (2011) 1.44
Aurora kinases as targets for cancer therapy. Cancer Treat Rev (2007) 1.33
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res (2011) 1.24
Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci (2006) 1.15
Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. Vet Comp Oncol (2011) 1.15
Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol (2011) 1.07
Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol (2007) 1.05
Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest (2009) 1.04
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer (2010) 1.04
Relationships between DNA fragmentation, chromatin condensation, and changes in flow cytometry profiles detected during apoptosis. Exp Cell Res (1995) 1.03
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2010) 0.98
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res (2010) 0.98
Analysis of apoptotic cells by flow and laser scanning cytometry. Methods Enzymol (2000) 0.97
Aurora kinases as prognostic biomarkers in ovarian carcinoma. Hum Pathol (2009) 0.97
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol (2010) 0.93
Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. J Am Vet Med Assoc (2006) 0.91
Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci (2012) 0.90
Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci (2006) 0.90
Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med (2012) 0.90
Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin"). Int J Radiat Oncol Biol Phys (2006) 0.89
IgG-mediated histamine release from canine mastocytoma-derived cells. Int Arch Allergy Immunol (2001) 0.88
Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study. Vet Comp Oncol (2011) 0.86
Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Vet Radiol Ultrasound (2002) 0.85
Variation among pathologists in histologic grading of canine cutaneous mast cell tumors. J Vet Diagn Invest (2005) 0.85
Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Vet Comp Oncol (2009) 0.84
Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. J Vet Pharmacol Ther (2010) 0.84
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer (2012) 0.83
A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Vet Comp Oncol (2010) 0.83
Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines. Vet Immunol Immunopathol (2010) 0.83
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. Oncol Rep (2010) 0.81
Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications. Histopathology (2011) 0.81
Establishment and characterization of a new canine mast cell tumor cell line. J Vet Med Sci (2001) 0.81
Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours. Vet Comp Oncol (2008) 0.81
Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours. Vet Res Commun (2006) 0.80
Radiation therapy for incompletely resected canine mast cell tumors. Vet Radiol Ultrasound (1998) 0.79
Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. Vet Pathol (2010) 0.79
Dependence of cell survival on iododeoxyuridine concentration in 35-keV photon-activated Auger electron radiotherapy. Int J Radiat Oncol Biol Phys (2011) 0.78
Kinase inhibitors in cancer therapy. Vet Comp Oncol (2004) 0.78
Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). J Am Anim Hosp Assoc (2010) 0.77
Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors. Vet Comp Oncol (2013) 0.77